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Abstract. The role of the latent TGF-[3 binding protein 
(LTBP) is unclear. In cultures of fetal rat calvarial cells, 
which form mineralized bonelike nodules, both LTBP 
and the TGF-[31 precursor localized to large fibrillar 
structures in the extracellular matrix. The appearance 
of these fibrillar structures preceded the appearance of
type I collagen fibers. Plasmin treatment abolished the 
fibrillar staining pattern for LTBP and released a com- 
plex containing both LTBP and TGF-[3. Antibodies and 
antisense oligonucleotides against LTBP inhibited the 
formation of mineralized bonelike nodules in long-term 
fetal rat calvarial cultures. Immunohistochemistry of fe- 
tal and adult rat bone confirmed a fibrillar staining pat- 
tern for LTBP in vivo. These findings, together with the 
known homology of LTBP to the fibrillin family of pro- 
teins, suggest a novel function for LTBP, in addition to 
its role in matrix storage of latent TGF-~, as a structural 
matrix protein that may play a role in bone formation. 
T GF-13 is secreted by virtually all cells in one or more 
latent forms that are biologically inert (Miyazono et 
al., 1988; Wakefield et al., 1988). Most cells secrete 
TGF-[3 as a 290-kD high molecular mass latent TGF-13 
complex that contains a 190-kD latent TGF-[3 binding pro- 
tein (LTBP) 1 linked by a disulfide bridge to the TGF-131 
precursor (also known as latency-associated peptide) (see 
Fig. 1) (Kanzaki et al., 1990; Tsuji et al., 1990). Platelets e- 
crete a latent complex with a 130-kD truncated form of 
LTBP. We have shown previously that osteosarcoma cells 
and bone organ cultures ecrete at least three forms of la- 
tent TGF-[3, including the 290-kD high molecular mass 
form (Bonewald et al., 1991; Dallas et al., 1994). However, 
bone cells are unique in that at least 50% of their latent 
TGF-13 is secreted as a 100-kD latent complex that lacks 
LTBP and consists only of the mature 25-kD TGF-[3 ho- 
modimer noncovalently associated with a 70-kD portion 
of the precursor homodimer. 
Mature (or active) TGF-[3 exerts effects in a variety of 
cell types. These can be broadly grouped into effects on 
matrix formation, inhibition of cell growth, and immuno- 
suppression (for reviews see Roberts and Sporn, 1990; 
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1. Abbreviation used in this paper: LTBP, latent TGF-13 binding protein. 
Border and Ruoslahti, 1992; Sporn and Roberts, 1992; 
Bonewald and Dallas, 1994; Centrella et al., 1994). Whereas 
many activities have been ascribed to active TGF-[3, the 
functions of the different latent TGF-[3 complexes are less 
clear. In particular, the function of the latent TGF-[3 bind- 
ing protein has not yet been defined. Although it was as- 
sumed initially to confer latency to the TGF-13 complex, it 
is now known that the 100-kD precursor complex that 
lacks LTBP is also latent, indicating that LTBP is not es- 
sential for latency (Gentry et al., 1987; Bonewald et al., 
1991). LTBP appears to play a role in assembly and secre- 
tion of the latent TGF-13 complex in human erythroleuke- 
mia cells (Miyazono et al., 1991). However, this does not 
seem to be the case in bone cells, where the 100-kD com- 
plex that lacks LTBP is efficiently secreted. Indeed, the rat 
osteosarcoma cell line UMR-106 secretes high amounts of 
latent TGF-13, and produces exclusively the 100-kD latent 
TGF-13 complex lacking LTBP (Dallas et al., 1994). Al- 
though it has been shown that LTBP may facilitate activa- 
tion of latent TGF-13 in co-cultures of endothelial and 
smooth muscle cells (Flaumenhaft et al., 1993), the possi- 
ble mechanism for this remains unclear. 
Sequence analysis of LTBP reveals anumber of features 
characteristic of matrix or adhesion molecules, which in- 
clude 16 EGF-like repeats, an RGD sequence, a putative 
calcium-binding domain, and an eight-amino acid motif 
identical to the cell-binding domain of [32-1aminin (Kan- 
zaki et al., 1990; Tsuji et al., 1990). Several of these lea- 
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ined by Western blotting and immunohistochemistry. Fi- 
nally, the effect of addition of antibodies and antisense 
oligonucleotides against LTBP was examined in long-term 
fetal rat calvarial cell cultures. These studies show that 
LTBP may be a structural fibrillar-type xtracellular ma- 
trix protein that plays an important role in the bone for- 
mation process. These findings may have implications for 
the role of LTBP in normal and pathological matrix 
formation in other tissues. 
Figure 1. Schematic diagram showing latent TGF-13 complexes 
that have been characterized in various cell types. The 100-kD re- 
combinant latent TGF-[3 complex consists of the mature 25-kD 
TGF-[3 homodimer  noncovalently associated with a 70-kD por- 
tion of the precursor homodimer  (Gentry et al., 1987). Bone cells 
secrete ~50% of their latent TGFq3 in a similar 100-kD precur- 
sor form (Bonewald et al., 1990). Most other cell types produce a 
high molecular weight latent TGF-I3 complex in which a third 
protein, the LTBP, is l inked to the precursor by a disulfide link- 
age (Miyazono et al., 1988; Wakefield et al., 1988; Kanzaki et al., 
1990; Tsuji et al., 1990). LTBP is 190 kD in fibroblasts and 130 kD 
in platelets, making latent TGF-13 complexes of 290 kD and 230 
kD respectively. *, internal cleavage site. 
tures are shared with the fibrillin family of extracellular 
matrix proteins (Sakai et al., 1986, 1991; Maddox et al., 
1989; Rosenbloom et al., 1993; Zhang et al., 1994). LTBP 
also contains a novel eight-cysteine r peat motif unique to 
the fibrillin family. Protein studies have confirmed that a 
large amount of LTBP, a proportion of which has TGF-13 
associated with it, is found in the extracellular matrix of fi- 
broblasts (Taipale et al., 1994). We hypothesized that in 
bone the 290-kD latent TGF-[3 complex containing LTBP 
targets latent TGF-[3 to bone matrix for storage, whereas 
the 100-kD form may be a secretory form, which is more 
readily available for cellular activation. Consistent with 
this hypothesis, Sato et al. (1993) have demonstrated that 
the 100-kD latent TGF-[3 is able to bind to the cell surface 
by an unknown mechanism. 
To determine whether LTBP could target the latent 
TGF-13 complex for matrix storage in bone cells, we used 
fetal rat calvarial cell cultures as a representative in vitro 
model of bone formation. These cells differentiate in vitro 
and form mineralized nodules with the characteristics of 
woven bone (Bellows et al., 1986; Harris et al., 1994). Mor- 
phologically distinct stages can be identified during the 
differentiation process (Dworetzky et al., 1990). In this 
study these were defined as the proliferating stage, the 
early (confluent) stage, the middle stage, where multilay- 
ered cellular nodules are beginning to form and the extra- 
cellular matrix is maturing, and the late stage, where the 
cellular nodules have become mineralized. We performed 
immunocytochemistry for LTBP, TGF-131 precursor, and 
type I collagen in long-term fetal rat calvarial cell cultures 
to examine the expression and possible colocalization of 
these molecules. LTBP was also localized in vivo by immu- 
nohistochemistry in frozen sections of long bones from 
young adult and fetal rats. We then determined the effect 
of plasmin digestion on the release of latent TGF-[3 com- 
plexes from the matrix of fetal rat calvarial cells as exam- 
Materials and Methods 
Materials 
Antibody against LTBP (Ab39) was a rabbit antiserum raised against na- 
tive LTBP purified from human platelets (Kanzaki et al., 1990). Antibody 
against the TGF-[31 precursor (LT-2) was a rabbit antiserum raised 
against recombinant TGF-[31 (Mizoi et al., 1993). Antibody against ma- 
ture TGF-[3 was a polyclonal rabbit antibody raised against porcine TGF- 
[31.2 obtained from R & D Systems, Inc. (Minneapolis, MN). Antibody 
against rat type I collagen was a rabbit polyclonal antiserum obtained 
from BIODESIGN International (Kennebunkport, ME). Recombinant 
human LTBP was generously donated by K. Takemura (Kirin Brewery 
Co. Ltd., Maebashi Gunma, Japan). Partially purified platelet latent TGF-[3 
complex was prepared in our laboratory as described previously (Bone- 
wald et al., 1991). Bovine plasmin was obtained from Sigma Chemical Co. 
(St. Louis, MO). Oligonucleotides were synthesized on a DNA/RNA syn- 
thesizer (Model 392; Applied Biosystems, Inc., Foster City, CA), and puri- 
fied using Poly Pak cartridges (Glen Research Corp., Sterling, VA) ac- 
cording to manufacturer's instructions. Sense and antisense nucleotides 
were made for the sequence GAGACTGCCCGCGATGG of rat LTBP, 
which includes the translation start site (Tsuji et al., 1990). 
Fetal Rat Calvarial Cell Cultures 
Unless stated otherwise, all tissue culture reagents were purchased from 
Life Technologies Inc. (Gaithersburg, MD) or JRH Biosciences (Lenexa, 
KS). The isolation of fetal rat calvarial cells was performed as described 
previously (Harris et al., 1994), using a modification of the method of Bel- 
lows et al. (1986). Briefly, frontal and parietal bones from ICR-Swiss rat 
fetuses (19-d gestation) were digested in 0.2% collagenase/0.05% trypsin 
in HBSS to obtain six sequential 20-min digests. The third through sixth 
digests were combined and grown to confluence in MEM, alpha modifica- 
tion (~-MEM) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml 
penicillin-streptomycin. At confluence the cells were trypsinized and 
plated for experiments at10,000 cells/cm 2 growth area. Long-term miner- 
alizing fetal rat calvarial cell cultures were maintained in u-MEM supple- 
mented with 5% FBS, 2 mM L-glutamine, 100 U/ml penicillin-streptomy- 
cin, 5 mM [3-glycerophosphate, and 100 ~g/ml L-ascorbic acid with or 
without est factors. Culture medium (including test factors) was changed 
every 3 d. For sense and antisense xperiments, fresh oligonucleotides 
were added to the cultures every 24 h. 
For quantitation of mineralized nodules in the fetal rat calvarial cell 
cultures, the cultures were fixed in neutral buffered formalin and stained 
by the Von Kossa method with Van Gieson's picric acid-acid fuchsin 
counterstain (Harris et al., 1994). The number and area of Von Kossa- 
stained nodules was then quantified by automated image analysis using a 
video analysis program (Jandel Scientific, San Rafael, CA) linked up to a 
videoscreen camera (CCD/RGB; Sony Corp., Park Ridge, NJ) and micro- 
scope (BH2; Olympus Corp,, Precision Instruments Division, Lake Suc- 
cess, NY) equipped with metallurgical lenses. 
Immunocytochemistry 
Immunocytochemistry was performed on cells grown in chamber slides 
(Lab-tek; Nunc Inc., Naperville, IL). These preparations were fixed for 10 
min in 95% ethanol. Immunocytochemistry wasalso performed on frozen 
sections of bone from young-adult Wistar rats (body wts 85-150 g) and fe- 
tal rats (19-d gestation, ICR-Swiss). Frozen tissue sections were obtained 
as described previously (Skerry et al., 1989). Briefly, fresh, undecalcified 
tissue was frozen by precipitate immersion in hexane cooled in a slurry 
bath of ethanol and dry ice. 8 txm cryostat sections were cut using a heavy- 
duty cryostat fitted with a tungsten carbide-edged blade (Bright Instru- 
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ments, Huntingdon, UK). The sections were collected onto slides coated 
with Vectabond (Vector Laboratories, Burlingame, CA) and were then 
fixed in chilled acetone for 5 min before immunohistochemical st ining. 
Endogenous peroxidase activity was blocked by preincubation i 3% 
hydrogen peroxide in PBS for 30 min at room temperature. Background 
blocking was performed by incubating specimens in 1% normal goat se- 
rum in PBS for 3 h at room temperature. Specimens were incubated in pri- 
mary antibody or control preimmune serum diluted in PBS/1% normal 
goat serum for 2 h at 37°C (1:2,000 dilution for Ab39, and 1:1,000 dilution 
for LT-2 and type I collagen antibodies). For detection an immunocy- 
tochemistry kit (Vectastain ABC-elite; Vector Laboratories, Inc., Burlin- 
game, CA) for rabbit IgG was used in combination with a DAB peroxi- 
dase substrate kit (brown reaction product) according to manufacturer's 
instructions (Vector Laboratories, Inc.). Some preparations were counter- 
stained for 2 rain with 1% methyl green before mounting. Other prepara- 
tions were also counterstained with alkaline phosphatase using an alkaline 
phosphatase ubstrate kit (red reaction product) according to manufac- 
turer's instructions (Vector Laboratories, Inc.). Cell culture preparations 
were mounted in aqueous mounting medium according to manufacturer's 
instructions (Crystal mount; Biomedia Corp., Foster City, CA). Cryostat 
tissue sections were dehydrated through graded alcohols and mounted in 
mounting medium (DPX; Fluka Chemika, Buchs, Switzerland). Specific- 
ity of immunostaining for LTBP was confirmed by preincubating the im- 
mune serum for 30 min with partially purified human platelet latent TGF-13 
(230 kD) or recombinant human LTBP (kindly donated by K. Takemura). 
For immunofluorescent staining a biotinylated goat anti-rabbit second 
antibody (Vector Laboratories, Inc.) was used in conjunction with strepta- 
vidin-FITC (Pierce, Rockford, IL). The preparations were then viewed on 
a confocal aser scanning microscope (LSM 10; Carl Zeiss Inc., Thoru- 
wood, NY). Fiber sizes were measured by image analysis. 
Treatment of Fetal Rat Calvarial Cell Preparations 
with Plasmin 
For immunohistochemical analysis of fetal rat calvarial cell cultures after 
plasmin treatment, the cells were grown on Lab-tek chamber slides as de- 
scribed above until the early stage of differentiation, where the cells had 
reached confluence and LTBP fibrillar staining was well developed (see 
Fig. 2). The cells were washed twice in PBS and incubated with plasmin 
(0.1 U/ml) in serum-free a-MEM medium for 1 h at 37°C. After incuba- 
tion with plasmin the cell cultures were fixed and stained for LTBP by im- 
munocytochemistry as described above. 
For Western blot analysis of plasmin-released latent TGF-[3 complexes, 
fetal rat calvarial cells were grown in six-well plates until the early stage of 
differentiation. The cells were then washed twice in PBS and lysed in ice- 
cold RIPA buffer (50 mM Tris-HC1, pH 7.2, 150 mM NaC1, 1% NP-40, 
0.5% sodium deoxycholate). The deoxycbolate-insoluble pellet (which 
consists predominantly of matrix proteins) was collected by centrifugation 
at 14,000 rpm for 10 min. The pellet was washed twice in PBS, and then di- 
gested with plasmin (0.1 U/ml) in serum-free a-MEM medium for 1 h. 
Proteins released by plasmin digestion were concentrated byprecipitation 
in 80% ethanol. The protein pellet was then dissolved in nonreducing 
sample buffer, heated at 95°C for 5 min, and analyzed by SDS-PAGE fol- 
lowed by Western blotting. 
Western Blot Analysis of Plasmin-released Latent 
TGF-fl Complexes 
Proteins released by plasmin digestion of extracellular matrices were ana- 
lyzed by SDS-PAGE using 5-12% gradient polyacrylamide gels as de- 
scribed previously (Bonewald et al., 1991; Dallas et al., 1994). The samples 
were run under nonreducing conditions (to keep the latent complexes in- 
tact). Proteins were then transferred onto a nitrocellulose membrane by 
electroblotting as described previously (Bonewald et al., 1991; Dallas et 
al., 1994). Membranes were blocked in 5% nonfat milk in TBS buffer (50 
mM Tris-HCl, 150 mM NaC1, pH 7.4) for 2 h at room temperature, and 
then incubated with either a rabbit polyclonal antiserum against LTBP 
(Ab39), a rabbit polyclonal antibody against mature TGF-[3 (R & D Sys- 
tems, Inc.), or control nonimmune antiserum. Antibody incubations were 
carried out in TBS buffer + 5% BSA. Immunostained bands were visual- 
ized using peroxidase-conjugated protein-A (Kirkegaard & Perry Labora- 
tories, Inc., Gaithersburg, MD) in conjunction with the enhanced chemilu- 
minescence detection system used according to manufacturer's in tructions 
(Amersham Corp., Arlington Heights, IL). 
Measurement ofLTBP by ELISA 
A single-sided ELISA was used to measure LTBP concentrations in con- 
ditioned media from fetal rat calvarial cell cultures treated with sense and 
antisense oligonucleotides against LTBP. This ELISA has a detection 
limit of 10-20 ng/ml LTBP. High protein-binding EIA/RIA 96-well plates 
(Costar Corp., Cambridge, MA) were coated overnight with test samples 
or recombinant LTBP standards diluted in PBS. Background blocking 
was performed for 2 h at 37°C in PBS/5% BSA. The plates were then incu- 
bated with antiserum against LTBP (Ab39, 1:1,000 dilution in PBS/0.5% 
BSA) for 1 h at 37°C. The detection antibody was an HRP-conjugated 
goat anti-rabbit antibody (Sigma Chemical Co.). O-phenylenediamine di- 
hydrochloride tablets (Sigma Chemical Co.) were used as the reaction 
substrate according to manufacturer's instructions. The reaction was 
stopped by the addition of 3 M HCl (25 p~l/100 Ixl reaction vol). The absor- 
bance at 492 nm was read, and LTBP concentrations in test samples calcu- 
lated by linear regression using the Immunofit EIA/RIA program, version 
3.00 (Beckman Instruments Inc., Fullerton, CA). 
Results 
Immunolocalization f LTBP in Fetal Rat 
Calvarial Cells 
LTBP staining was cytoplasmic n subconfluent, proliferat- 
ing fetal rat calvarial cultures (Fig. 2 A). Two days after 
the cells became confluent, LTBP staining was no longer 
cytoplasmic, but was localized in large fibrillar structures 
in the extracellular matrix, which appeared to form an or- 
ganized network throughout the culture (Fig. 2 B). As the 
cultures began to differentiate and cellular nodules began 
to form by days five through eight of culture, the LTBP 
fibrillar structures appeared organized around and be- 
tween the nodules and actually appeared to span between 
nodules, linking them together (Fig. 2 C). This pattern of 
staining was maintained in the cultures when the nodules 
had become mineralized after 9-16 d of culture (Fig. 2 D). 
Specificity of the antibody was confirmed by preincubat- 
ing the antibody with an excess of partially purified plate- 
let-derived latent TGF-13 or recombinant LTBP (data not 
shown). These controls appeared identical to the preim- 
mune controls hown in Fig. 2, E-H. 
Confocal immunofluorescent depth profiles through the 
developing nodules, such as the example shown in Fig. 2 I, 
revealed that the LTBP fibers were located almost exclu- 
sively in the cell layers at the bottom of the nodule, and 
did not penetrate the cell layers higher in the nodule. Thus 
it appeared that the bone nodule formed on top of the cell 
layer containing an organized network of LTBP fibers. 
LTBP Immunolocalization in Adult Rat Bone 
In the young adult rat ulna, LTBP expression was found in 
a zone encircling the whole circumference of the bone. 
This corresponds to the fibrous periosteum, the layer of 
cells peripheral to the alkaline phosphatase-positive os- 
teoblastic layer (Fig. 3 A). The staining was fibrillar, al- 
though here the fibers are in cross section. The fibrillar na- 
ture of the LTBP staining is more clearly demonstrated in 
the connective tissue of the interosseous ligament hat 
runs between the radius and ulna (Fig. 4, B and C) from 
which measurements of the fiber sizes were made using 
image analysis. 
LTBP Staining in Fetal Rat Long Bones 
Fig. 3 C shows an oblique cryostat section through the de- 
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Figure 2. Immunolocalization of LTBP (brown immunoperoxidase staining with methyl green counterstain) in long-term cultures of fe- 
tal rat calvarial cells using a polyclonal antiserum against LTBP (A-D) with preimmune serum controls (E-H). Bar, 100 txm. (A) Prolif- 
erating fetal rat calvarial cell cultures howing cytoplasmic localization of LTBP. (B) 2 d after reaching confluence (early stage) LTBP is 
localized to large fibrillar structures which form an organized network throughout the cultures. (C) 8 d after reaching confluence (mid- 
dle stage) the fetal rat calvarial cell cultures are forming multilayered cellular nodules. The large fibrillar structures which stain posi- 
tively for LTBP are organized around and between the developing nodules. (D) 15 d after reaching confluence the cellular nodules have 
become mineralized (late stage). The organization of LTBP-positive fibers spanning between mineralized nodules is maintained. (E-H) 
Preimmune serum controls for (A-D), respectively. (/) Confocal immunofluorescence depth profile through a developing nodule from a 
fetal rat calvarial cell culture at the middle stage stained for LTBP. Color scale indicates the distance of each structure from the surface 
of the culture plate (blue) to the top of the nodule (red). Bar, 50 Ixm. 
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Figure 3. Immunolocalization of LTBP in the ulnae of young adult rats and the tibiae and metatarsals of 19-d fetal rats using a polyclonal 
antiserum against LTBP (A, C, E) with preimmune serum controls (B, D, F). Immunoperoxidase staining for LTBP (brown) with alka- 
line phosphatase histochemical stain (red) and methyl green nuclear counterstain. Bar, 100 ~tm. (A) LTBP staining (black arrows) sur- 
rounding a transverse section of a young adult rat ulna. Staining is present in the fibrous periosteum peripheral to the alkaline phos- 
phatase-positive osteoblast layer (white arrows). Staining is fibrillar, although ere the fibers are in cross section. (B) Preimmune serum 
control, serial section t  A. (C) oblique section of a 19 d fetal rat tibia showing LTBP staining (black arrows) adjacent to the alkaline 
phosphatase positive layer (white arrows) of the developing periosteum. (D) Preimmune serum control, serial section to C. (E) LTBP 
staining completely surrounds and delineates the developing metatarsals in this section of a 19-d fetal rat limb and extends into the car- 
tilaginous matrix. (F) Preimmune control, serial section to E. 
veloping tibia of a 19-d fetal rat. LTBP staining was local- 
ized in the developing periosteum in the layer of cells adja- 
cent to the alkaline phosphatase-posit ive osteoblast layer, 
similar to the staining pattern in the young adult rat. There 
was a small zone of overlap where the cells were positive 
for both LTBP and alkaline phosphatase. In developing 
fetal rat metatarsals (Fig. 3 E) that had not yet begun to 
mineralize, LTBP staining completely surrounded and de- 
l ineated the developing cartilaginous bone rudiments. At  
higher magnification it could be seen that LTBP staining 
also extended partway into the cartilage matrix in certain 
areas (data not shown). There was evidence of fibrillar 
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from 0.6 to 1.2 I~m in diameter. In growing adult rat bones, 
the fibrillar nature of the LTBP staining was most evident 
in the interosseus ligament hat connects the radius and 
ulna (Fig. 4 B). Fiber measurements made from this region 
indicated that the fibers ranged from 0.7 to 1.3 }xm in di- 
ameter, which was almost an identical size to the fiber 
sizes measured in vitro. 
Figure 4. (A) Confocal immunofluorescence micrograph showing 
examples of LTBP fibrillar structures in a confluent fetal rat cal- 
varial cell culture which were measured using image analysis, Fi- 
ber sizes ranged from 0.6-1.2 ~m in diameter. Bar, 10 ixm. (B) 
Immunoperoxidase staining of LTBP fibrillar structures (arrows) 
in the interosseous ligament between the radius and ulna of a young 
adult rat. Bar, 100 Ixm. (C) Higher power computer enhanced im- 
age showing examples of fibers measured by image analysis. Fi- 
ber sizes ranged from 0.7-1.3 ~m in diameter. Bar, 10 Ixm. 
staining in some areas, but the fibrillar staining pattern 
was not as well developed as in the young adult rat. 
Size Measurement ofLTBP Fibrillar Structures 
The LTBP fibrillar structures in fetal rat calvarial cell cul- 
tures were measured by image analysis using confocal im- 
munofluorescence microscopy (Fig. 4 A). Fibers ranged 
Immunolocalization f TGF-fll Precursor and Type I
Collagen in Fetal Rat Calvarial Cells 
Immunostaining for TGF-131 precursor also revealed fi- 
briUar structures in the extracellular matrix of postconflu- 
ent cultures of fetal rat calvarial cells (Fig. 5 B). Although 
the fibrillar staining with anti-TGF-131 precursor was not 
as pronounced as with anti-LTBP (Fig. 5 A), the fibers 
were of similar size, suggesting that the LTBP fibriUar 
structures probably had TGFq31 associated with them. In 
contrast, staining for type I collagen was distinctly differ- 
ent from that seen with LTBP. At 2 d after confluence, 
when a well-organized network of LTBP fibers was al- 
ready formed (Fig. 5 A), staining for type I collagen was 
still predominantly cytoplasmic, with only a few collagen 
fibers visible in the extracellular matrix (Fig. 5 C). Col- 
lagen fibers were not abundant in the extracellular matrix 
until the middle stage of differentiation at ~5--6 d after 
confluence. Thus the appearance of LTBP fibrillar struc- 
tures in the extracellular matrix preceded the appearance 
of type I collagen fibers. 
Effect of Plasmin Treatment on LTBP 
Immunostaining and Release of Latent TGF-fl 
Complexes from the ExtraceUular Matrix of 
Fetal Rat Calvarial Cells 
Taipale et al. (1994) have reported previously that LTBP 
is covalently linked to the extracellular matrix of fibro- 
blasts, but that latent TGF-13 complexes containing pro- 
teolytic fragments of LTBP are released by digestion with 
plasmin. In the present study, treatment of fetal rat calva- 
rial cell cultures with plasmin (0.1 U/ml) abolished the 
fibrillar staining for LTBP in the extracellular matrix (see 
Fig. 6, A and B). Disappearance of the flbrillar staining co- 
incided with the release of both LTBP and TGF-[3 from 
the extracellular matrix of fetal rat calvarial cells. These 
were present in a high molecular weight latent TGF-[3 
complex which migrated slightly greater than 200-kD un- 
der nonreducing conditions (see Fig. 6 C). This agrees well 
with the band sizes reported by Taipale et al. (1994), and 
probably represents a high molecular weight latent TGF-[3 
complex consisting of the 100-kD precursor form of latent 
TGF-I3 complexed to an ,-~120-kD proteolytic fragment of 
LTBP. A higher molecular weight doublet was also seen 
with anti-LTBP antibodies which may represent aggre- 
gates of LTBP molecules. Antibodies to TGF-I3 appeared 
to recognize only the lower band of the high molecular 
weight doublet, indicating that this form also had TGF-13 
associated with it. Consistent with the Western blot data, 
plasmin treatment of fetal rat calvarial cell cultures also 
resulted in an increase in the amount of latent TGF-[3 de- 
tectable in the conditioned medium by bioassay (data not 
shown). 
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Figure 5. Immunolocalization f 
(A) LTBP, (B) TGF-[31-precur- 
sor, (C) type I collagen in fetal 
rat calvarila cell cultures com- 
pared with (D) nonimmune se- 
rum control. Immunoperoxidase 
staining was performed with no 
counterstain. Bar, 100 t~m. (A) 
LTBP fibrillar structures are 
present in a well-formed net- 
work by 2 d after confluence in 
early fetal rat calvarial cell cul- 
tures. (B) TGF-[31 precursor lo- 
calizes to similar fibrillar struc- 
tures in the extracellular matrix. 
(C) type I collagen staining is 
still predominantly cytoplasmic 
at this stage of culture, with only 
a few collagen fibers present in 
the extracellular matrix. Col- 
lagen fibers are not abundant in 
the extracellular matrix until day 
5-6 after confluence. (D) Non- 
immune control. 
Effect o f  Antibodies and Antisense 
Oligonucleotides to LTBP on Bone Nodule Formation 
in Fetal Rat Calvarial Cell Cultures 
To determine whether the LTBP fibrillar structures played 
any role in the formation of mineralized bone nodules in 
fetal rat calvarial cell cultures, the cultures were treated 
with antibodies or antisense oligonucleotides directed 
against LTBP. When antibodies to LTBP were added 
throughout he 12-d culture period they inhibited bone 
nodule formation in a dose-dependent manner (Fig. 7, A 
and B). Both the number and size of the bone nodules was 
inhibited. Antisense oligonucleotides against LTBP also 
inhibited bone nodule formation moderately, but signifi- 
cantly, compared with control sense oligonucleotides (Fig. 
7, C and D). When conditioned media samples were col- 
lected after 3 d of treatment, antisense oligonucleotides to 
Figure 6. (A and B) Immu- 
nolocalization of LTBP and 
(C) Western blot analysis of 
LTBP and TGF-13 after treat- 
ment of fetal rat calvarial cell 
cultures with 0.1 U/ml plas- 
min. Immunoperoxidase stain- 
ing was performed with no 
counterstain. Bar, 100 Ixm. (A) 
Control culture stained with 
anti-LTBP showing fibrillar 
staining pattern, (B) culture 
treated with 0.1 U/ml plasmin 
for 1 h then stained with anti- 
LTBP. Fibrillar staining is abolished, (C) Western blot analysis of latent TGF-13 complexes released by plasmin treatment ofthe extracellular 
matrix from fetal rat calvarial cells (nonreducing gel). A complex slightly greater than 200 kD is seen (arrow) which reacts with both anti- 
LTBP and anti-TGF-13 antibodies. 
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Figure 7. Histograms showing the effects of treatment with anti- 
serum (A and B) and antisense oligonucleotides (C and D) 
against LTBP on the number and area of mineralized nodules 
formed in long term cultures of fetal rat calvarial cells. *, signifi- 
cantly decreased compared with preimmune serum control or 
sense oligonucleotide control. P < 0.05 (ANOVA/student-New- 
man-Keul's method of multiple comparisons). (A andB) I-q, con- 
trol; II, anti-LTBP; and [], nonimmune. (C and D) El, control; II, 
LTBP-antisense; and [], LTBP-sense. 
LTBP at the 5-1xM dose were found to reduce significantly 
the amount of LTBP protein secreted by the cells as mea- 
sured by ELISA (see Table I). Other supportive data for a 
role for LTBP in bone formation in vitro includes reduc- 
tion of the number and size of mineralized bone nodules 
formed in cultures of fetal rat calvarial cells treated with 
plasmin, which releases LTBP from the extracellular ma- 
trix (data not shown). 
To determine whether active TGF-13 was also playing a 
role in bone nodule formation in vitro, fetal rat calvarial 
cell cultures were treated with antibodies to TGF-131 and 
TGF-132. These antibodies had essentially no effect on ei- 
ther the number or size of the nodules (data not shown). 
This suggests that, in contrast to LTBP, active TGF-13 does 
not play a significant role in bone formation in vitro. 
Table I. Concentrations ofLTBP in Conditioned Media from 
Fetal Rat Calvarial Cell Cultures Treated with Sense and 
Antisense Oligonucleotides against LTBP (as shown in Fig. 7, 
C and D) 
LTBP concentration 
Control 
LTBP sense 
LTBP antisense 
ng/ml 
196.1 _+ 11,2 
5.0 I~M 176.9 _+ 1.3 
0.5 ixM 165.0 + 2.0 
5.0 txM 81.1 _+ 3.9* 
0.5 txM 186.9 _+ 7.6 
Data are mean - SEM from triplicate wells. 
* Significantly decreased compared with sense control, P < 0.05 (ANOVA/student- 
Newman-Keul's method of multiple comparisons). 
Discuss ion  
In this study we have clearly demonstrated that LTBP lo- 
calizes to large (0.6-1.3 ~m) fibrillar structures in the ex- 
tracellular matrix of bone cells in vitro and in vivo. Al- 
though these observations are entirely consistent with the 
hypothesis that LTBP targets latent TGF-13 to the extra- 
cellular matrix for storage, they also suggest a previously 
undescribed role for this protein as a structural extracellu- 
lar matrix protein. The fibrillar localization of LTBP is 
particularly interesting in view of the homology of LTBP 
to the fibrillins. Fibrillins 1 and 2 have been identified, and 
a fibrillin-like protein has also been reported (Sakai et al., 
1986, 1991; Rosenbloom et al., 1993; Zhang et al., 1994). 
These proteins are a major component of connective tis- 
sue microfibrils and share a number of features with LTBP 
including multiple EGF-like repeats, an RGD sequence, a 
putative calcium-binding domain, and a novel eight-cys- 
teine repeat motif which is unique to this family of pro- 
teins. This suggests that there may be a whole gene family 
of fibrillin-like proteins that are involved in the formation 
of microfibrils and that have important structural roles in 
maintaining tissue integrity and organization. 
A number of other unrelated proteins have been shown 
to be constituents of microfibrils. These include a 78-kD 
microfibrillar protein (MP78) and a 31-kD protein called 
microfibril-associated glycoprotein (Gibson et al., 1989). 
In some tissues, microfibrils may be associated with elastin 
to form elastic fibers (for review see Rosenbloom et al., 
1993) and a recent report has shown that the proteoglycan 
versican is associated with elastic fibers in the dermis 
(Zimmerman et al., 1994). Thus it appears that microfibrils 
may be composed of a number of constituent proteins, 
whose relative proportions vary in different issues, thus 
defining structural and functional characteristics specific 
for each tissue (Davis, 1994). A second latent TGF-[3 bind- 
ing protein (LTBP-2) recently has been isolated which has 
41% homology of LTBP (Mor6n et al., 1994) and it seems 
probable that the LTBPs will be classified as new mem- 
bers of the growing family of fibrillin-like proteins in- 
volved in the formation of connective tissue microfibrils. 
This hypothesis i currently under investigation i our lab- 
oratory and preliminary data indicate that, like fibrillin, 
some of the LTBP fibrillar structures colocalize with elas- 
tic fibers in the young adult rat ulna, but that other LTBP 
fibers exist independently of any elastin (Dallas, S. L., un- 
published observations). 
The fibrillar localization of LTBP in the extracellular 
matrix of bone cells is clearly consistent with a role for this 
molecule in storing latent TGF-[3 in the matrix. This idea is 
supported by the finding that immunostaining for TGF- 
[M-precursor reveals similar fibrillar structures in the ex- 
tracellular matrix of fetal rat calvarial cells. Furthermore, 
the demonstration that loss of fibrillar LTBP staining after 
treatment with plasmin is associated with release of both 
LTBP and TGF-13 in a high molecular weight complex 
provides further evidence that the LTBP fibers do have 
TGF-13 associated with them. 
Our data support hose of Taipale et al. (1994) showing 
that LTBP complexed to TGF-[~ can be released from the 
extracellular matrix of fibroblasts by plasmin treatment. 
This finding may be very significant in view of the poten- 
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tial role of plasmin in activation of latent TGF-13. It is well 
established that plasmin is able to activate the precursor 
form of latent TGF-[3 in the test tube (Lyons et al., 1988; 
1990). The plasminogen-plasminogen activator system 
may also be involved in the activation of latent TGF-13 ob- 
served in co-cultures of endothelial and smooth muscle 
cells (Sato and Rifkin, 1989) and in osteoblasts stimulated 
by parathyroid hormone (Yee et al., 1993). Expression of 
plasminogen activator is regulated by numerous agents, in- 
cluding osteotropic factors such as parathyroid hormone 
(Hamilton et al., 1985; Pfeilschifter et al., 1990; Yee et al., 
1994). Therefore the plasminogen-plasminogen activator 
system may mediate the effects of agents uch as parathy- 
roid hormone on TGF-[3 activity. The observations of the 
present study together with those of Taipale et al. (1994) 
indicate that plasmin is able not only to activate soluble 
forms of latent TGF-13, but is also able to access matrix- 
bound stores of latent TGF-[3 through cleavage of LTBP. 
This may have important consequences for tissue repair 
and wound healing, and release of matrix-bound latent 
TGF-13 may be one of the mechanisms through which plas- 
min exerts its effects on matrix remodeling. 
In nodule-forming fetal rat calvarial cell cultures the 
LTBP fibrillar structures were located in the cell layers un- 
derneath the bone nodule. In vivo LTBP was found in an 
analogous distribution, surrounding the bone and adjacent 
to the alkaline phosphatase-positive bone forming osteo- 
blasts. These observations, together with the evidence that 
antibodies and antisense oligonucleotides against LTBP 
inhibited nodule formation, indicate that formation of the 
LTBP fibrillar structures may be an important event for 
subsequent bone formation to occur. It seems unlikely that 
this is a process pecific to bone cells, but rather that the 
LTBP flbrillar structures are involved in maintaining the 
structural integrity of the tissue or cell monolayer, which 
may be a prerequisite for bone formation to occur. Thus, 
the LTBP fibers may form a "scaffolding" upon which the 
bone subsequently forms. An alternative possibility is that 
the LTBP fibrillar structures are involved in cell migration 
and organization, and that the arrangement of LTBP fi- 
bers may determine where bone will form. These hypothe- 
ses are currently under investigation. 
It is well documented that TGF-13 autoinduces its own 
mRNA expression in several cell types (Van Obberghen- 
Schilling et al., 1988; Bascom et al., 1989; Kim et al., 1989, 
1990). TGF-[3 has also been shown to stimulate xpression 
of numerous matrix proteins that include fibronectin and 
the fibronectin receptor, collagen, elastin, tenascin, throm- 
bospondin, biglycan, and vitronectin (Ignotz and Mas- 
sagu6, 1986; Penttinen et al., 1988; Roberts et al., 1988; 
Rossi et al., 1988; McKay et al., 1993; Marigo et al., 1994). 
We have shown previously that TGF-I3 is able to stimulate 
expression of mRNA and protein for both TGF-13 and 
LTBP in osteosarcoma cells (Dallas et al., 1994) and have 
recently confirmed a similar effect in subconfluent fetal rat 
calvarial cells (Dallas, S. L., unpublished observations). 
The addition of LTBP to the list of extracellular matrix 
proteins whose expression is stimulated by TGF-[3 further 
emphasizes the importance of this molecule in inducing 
new extracellular matrix formation. TGF-13 also promotes 
matrix accumulation by inhibiting the expression of the 
proteases that might degrade matrix proteins while stimu- 
lating expression of protease inhibitors (Edwards et al., 
1987; Laiho et al., 1987; Kubota et al., 1991; Tomooka et 
al., 1992). Thus TGF-[3 promotes extracellular matrix ac- 
cumulation by exerting control at multiple levels. The in- 
corporation of latent TGF-[3 into the matrix through bind- 
ing to LTBP may represent another level of control for 
TGF-13, whereby it can exert effects on cells at a later date 
• after release from the matrix and subsequent activation. 
This may be particularly important in tissue repair, where 
TGF-13 appears to play a pivotal role in determining 
whether healing will be normal as in wound healing, or 
pathological s in scarring and fibrotic diseases. 
An interesting finding was that in fetal rat calvarial cell 
cultures, a well-organized network of LTBP fibers was 
clearly visible by two days after confluence, which is well 
before type I collagen fibers became abundant in the ex- 
tracellular matrix at five to six days after confluence. Al- 
though this does not rule out the possibility that the fibril- 
lar LTBP staining occurs as a result of its binding to other 
fibrillar matrix protein(s), such as the fibrillins or fibronec- 
tin, it does indicate that LTBP is not colocalizing with type 
I collagen, the most abundant matrix protein in bone. The 
fact that the LTBP fibrillar staining precedes the appear- 
ance of collagen fibers in the extracellular matrix suggests 
that it may be one of the earliest proteins to appear in the 
matrix. Preliminary data in our laboratory indicate that 
LTBP expression is increased in certain fibrotic disease 
states. Therefore an understanding of the mechanisms for 
regulation of LTBP expression may be of great clinical im- 
portance in treating fibrotic disease states, particularly 
since excess TGF-13 may play a major causative role in 
these conditions (Border et al., 1992). 
In conclusion, this study is the first demonstration that 
the latent TGF-[3 binding protein is a structural extracellu- 
lar matrix protein involved in the formation of large fibril- 
lar structures in the extracellular matrix of bone cells• 
LTBP appears to play a role in bone formation in vitro 
and its localization in vivo is also suggestive of a role in 
bone development and formation. Future studies are re- 
quired to elucidate further the role of this protein in bone 
formation, particularly in view of recent reports that Mar- 
fan syndrome and related disorders of the cardiovascular 
and skeletal systems have been linked to mutations in genes 
for the fibrillin family of extracellular matrix proteins of 
which LTBP may be a new member (Dietz et al., 1991; Lee 
et al., 1991; Maslen et al., 1991; Milewicz et al., 1992; L6nn- 
qvist et al., 1994). TGF-13 may be the first example of a 
growth factor whose latent form is complexed to a protein 
which actually appears to function as a structural matrix 
protein, and may play a role in both storage of the mole- 
cule in the matrix and its subsequent release and activa- 
tion. This may be a precedent for other growth factors, 
and could represent an exquisite system for the fine regu- 
lation of growth factor actions. 
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